Steinberganna Wealth Management Takes $1.15 Million Position in Zoetis Inc. $ZTS

Steinberganna Wealth Management purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,849 shares of the company’s stock, valued at approximately $1,149,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Scott & Selber Inc. boosted its stake in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the period. North Star Asset Management Inc. raised its stake in shares of Zoetis by 4.9% in the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company’s stock valued at $225,000 after acquiring an additional 67 shares during the period. Secure Asset Management LLC lifted its holdings in shares of Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock worth $382,000 after acquiring an additional 68 shares during the last quarter. Moment Partners LLC boosted its position in shares of Zoetis by 3.2% during the 2nd quarter. Moment Partners LLC now owns 2,354 shares of the company’s stock worth $367,000 after purchasing an additional 72 shares during the period. Finally, CVA Family Office LLC increased its holdings in Zoetis by 6.7% in the 2nd quarter. CVA Family Office LLC now owns 1,173 shares of the company’s stock valued at $183,000 after purchasing an additional 74 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.9%

ZTS opened at $126.77 on Friday. The business has a fifty day moving average price of $123.63 and a 200 day moving average price of $140.93. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The stock has a market capitalization of $55.87 billion, a price-to-earnings ratio of 21.34, a PEG ratio of 2.55 and a beta of 0.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue for the quarter was up .5% on a year-over-year basis. During the same period in the previous year, the company posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be given a dividend of $0.53 per share. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is presently 35.69%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ZTS shares. JPMorgan Chase & Co. decreased their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Barclays began coverage on Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective on the stock. Stifel Nicolaus lowered their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a report on Tuesday, November 18th. BTIG Research reaffirmed a “buy” rating and issued a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Finally, HSBC set a $140.00 price target on shares of Zoetis in a research report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $160.18.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.